Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALKAZAR: NVL-655 vs alectinib in first-line ALK-positive advanced NSCLC
2024-517553-26-00Phase 3Authorised
- Sponsor
- Nuvalent
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 28
01
Overview
Phase 3, randomised, double-blind trial of neladalkib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Nuvalent. Primary endpoint: Progression-free survival (PFS). Planned start Jun 2025; status: authorised.
02
Drugs
neladalkib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-517553-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517553-26-00.